To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
OE Original Cover

Tanezumab Versus NSAIDs in the Treatment of Hip or Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Share
Cite This
+ Favorites
Share
Cite This
+ Favorites
July 11, 2022

Tanezumab Versus NSAIDs in the Treatment of Hip or Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Vol: 5| Issue: 7| Number:2| ISSN#: 2563-559X

Authored By: Meng Zhu, Yaping Chang, Steve Phillips, Ellen Scholl, Selina Bains, Mohit Bhandari on behalf of OrthoEvidence

Banner Image
Highlights
  • In the present OE Original, we conduct a systematic review and meta-analysis to examine evidence from randomized controlled trials (RCTs) comparing the efficacy and safety of tanezumab (2.5 mg or 5 mg) administered intravenously or subcutaneously with oral non-steroidal anti-inflammatory drugs (NSAIDs) in patients with hip or knee osteoarthritis (OA).

 

  • Six studies, representing 4 RCT cohorts, were identified. All studies were sponsored by Pfizer.

 

  • Tanezumab 2.5 mg significantly improved WOMAC pain, WOMAC function, and PGA only at 4 weeks post treatment, but not at 16 weeks after treatment. In addition, tanezumab 2.5 mg resulted in an elevated risk of developing rapidly progressive OA, compared to NSAIDs.

 

  • Tanezumab 5 mg, more efficacious than 2.5 mg tanezumab, markedly improved all efficacy outcomes at both 4 weeks and 16 weeks post treatment. However, such benefits might not be clinically important. More importantly, tanezumab 5 mg raised more safety concerns: it significantly increased the risk of developing any adverse event, rapidly progressive OA, and abnormal peripheral sensation, compared to oral NSAIDs.

 

  • There lacks convincing evidence demonstrating that the benefits of tanezumab 2.5 mg or 5 mg outweigh the harms.

SHARE THIS OE ORIGINAL

Loading...

Join the Conversation

Please Login or Join to leave comments.

Frank Smith 2022-07-14

Orthopaedic Surgeon - Canada

Very disappointing longer term findings after a promising start.So many studies copy this direction: steroid injections, partiai meniscectomies etc. The role of more modern regenerative medicine needs deeper study than any done so far by OE.